ondasdechoque.org
PT-BR

Neck and trapezius myofascial pain · Randomized trial · 2012

Does low-energy shockwave ease upper-shoulder muscle pain?

In this trial, four sessions of focused shockwave over two weeks lowered pain on pressing the sore spot from about 5 to about 2 out of 10. With a very-low-energy sham, it went from about 5 to just over 4. People could also bear firmer pressure after shockwave.

Helped more than a very-low-energy sham
adults with upper-shoulder muscle pain
22
sessions, twice a week
4
weeks of treatment, checked right after
2

Good to know: No one had medicine, physio or exercise for the pain during the study.

Ji HM, Kim HJ, Han SJ Annals of Rehabilitation Medicine, 2012 · Read the paper ↗

How this study worked

Shockwave11 peopleVery-low-energy sham11 peopleShockwaveSham
People were assigned by lot. One group had a sham: the same-looking treatment without the active waves. Each dot is one person.

What happened

Pain when the sore spot is pressed

0–10 pain scale · start and right after the fourth session

StartAfter 4 sessions

With shockwave, pain on pressing the sore spot fell from about 5 to about 2 out of 10. With the very-low-energy sham it went from about 5 to just over 4.
Show the numbers
GroupPeopleStartAfter 4 sessions
Shockwave94.912.27
Very-low-energy sham114.894.44

The treatment

Shockwave

Focused, twice a week for 2 weeks

Focused wavesMeet at a focal zone below the skin
Sessions
4, two a week
Pulses
700 per point · on the tight band, plus 300 around it
Strength
0.056mJ/mm²
Numbing
Not mentioned
Device
Dornier AR2

Compared with: A sham with very low energy (0.001 mJ/mm²), with sound to keep it convincing

Settings are what each study used, not a prescription.

Who took part

22 adults with muscle pain and tight, tender bands in the upper trapezius (the muscle on top of the shoulder). Of the 20 analysed (aged 25 to 74), 17 were women.

hollow squares: no final score

Shockwave9 of 11 measured
Very-low-energy sham11 people
20 of 22 people (91%) had a final score.

Side effects

No one stopped because of side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults with upper-trapezius myofascial pain syndrome; 22 recruited and 20 analyzed (9 treated, 11 control), ages 25–74 years, 3 men and 17 women among analyzed participants.

Low-energy focused ESWT11randomized

Eleven participants were assigned to this arm; two withdrew for geographic access, leaving nine analyzed.

Very-low-energy sham-like control11randomized

Eleven participants were assigned to this arm; all eleven were analyzed.

Pain at pressure threshold, 10-cm visual analogue scale1 reported outcome
01
Immediately after fourth session; baseline before first session

Pain at pressure threshold, 10-cm visual analogue scale

Visual analogue scale (VAS), 10 cm VAS points

BaselineFollow-up
Low-energy focused ESWT
2.27
Very-low-energy sham-like control
4.44
010 VAS points
means
GroupnBaselineFollow-up
Low-energy focused ESWT94.91 (SD 1.76)2.27 (SD 1.27)
Very-low-energy sham-like control114.89 (SD 1.76)4.44 (SD 2.13)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp <0.05

Between-group comparison immediately after session four

Mann–Whitney test

Authors report a statistically significant between-group difference after treatment (p<0.05), without exact p-value or effect estimate.

Analysis details and source

Baseline and follow-up means reported. Within-group treated change was significant and control change nonsignificant by Wilcoxon (p<0.05 reported for treated); this is distinct from the between-group test. The control baseline VAS is inconsistent in the source: 4.88 in the Results paragraph ‘Distribution of age and sex’ and 4.89 (printed twice) in the next paragraph, ‘A change of pain before and after the therapy’; the abstract gives no control value. The displayed value follows the later paragraph (4.89).

Pressure-pain threshold1 reported outcome
02
Immediately after fourth session; baseline before first session

Pressure-pain threshold

Digital algometer N

means
GroupnBaselineFollow-up
Low-energy focused ESWT940.36 (SD 9.94)61.2 (SD 12.16)
Very-low-energy sham-like control1143.67 (SD 10.27)45 (SD 9.17)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp <0.05

Between-group comparison immediately after session four

Mann–Whitney test

Authors report a statistically significant between-group difference after treatment (p<0.05), without exact p-value or effect estimate.

Analysis details and source

Baseline and follow-up means reported. Within-group treated change was significant and control change nonsignificant by Wilcoxon (p<0.05 reported for treated); this is distinct from the between-group test.

How treatment was delivered
Device and modality

Dornier AR2 electromagnetic focused shock-wave generator with cylindrical coil and parabolic reflector.

Active dose and target

0.056 mJ/mm²; 700 impulses on taut band and 300 around it.

Control dose

0.001 mJ/mm², described by authors as ineffective; sound used to help maintain participant blinding.

Sessions and co-interventions

Four sessions, twice weekly for two weeks. No medication, physiotherapy or exercise for myofascial pain during the study.

Anesthesia

No local anesthesia reported.

HARMS & TOLERABILITY

Two treated participants withdrew for geographic access, not side effects. Authors report no withdrawals due to therapy side effects; systematic adverse-event counts are not presented.

LIMITS OF THE ANALYSIS

Sex imbalance and limited age distribution among the 20 participants analyzed.

Single-blind design; examiner knew allocation.

Disease duration not collected; measurements only before and immediately after session four. Durability is unknown.

Table 1 is an image in raw XML and unavailable for visual inspection. Numeric values were taken from narrative text; image-only data were not inferred.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Sex imbalance and limited age distribution among the 20 participants analyzed.
  • Single-blind design; examiner knew allocation.
  • Disease duration not collected; measurements only before and immediately after session four. Durability is unknown.
  • Table 1 is an image in raw XML and unavailable for visual inspection. Numeric values were taken from narrative text; image-only data were not inferred.
Research review

Source-linked critical reading

Randomized comparative clinical trial

Reading depthMaterial consulted
Technical source record

Complete article XML, all nine section records, Table 1 caption and Figure 1–2 captions reviewed. Raw XML confirms Table 1 is embedded as an image, not a structured table. Image assets were unavailable; numeric outcomes and arm characteristics come only from the article narrative.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

Single-blind randomized controlled study. Twenty-two patients were recruited; 20 were analyzed after two participants in the treated group withdrew for geographic-access reasons.

Participants

Participants had shoulder pain and myofascial pain syndrome diagnosed using Simon’s criteria. The analyzed sample was 20: 9 treated and 11 control; 3 men and 17 women, ages 25–74 years (overall mean 33.35, SD 12.25). The source inconsistently reports control baseline VAS as 4.88 in the first Results subsection and 4.89 in the second (the abstract gives no control value); 4.89 is retained in the displayed data. Table 1 was image-only and its cells could not be verified.

Intervention

A Dornier AR2 electromagnetic focused device was used. The treated group received 0.056 mJ/mm², 700 impulses on the taut band and 300 around it, for four sessions (twice weekly for two weeks). No other myofascial-pain treatment was allowed. The control received 0.001 mJ/mm², described as ineffective but with sound intended to preserve blinding.

Comparator

Very-low-energy ESWT (0.001 mJ/mm²), described as a sham-like control. There was no separate usual-care or no-treatment arm.

Outcomes

Pain was assessed on a 10-cm VAS anchored 0 (no pain) to 10 (maximum unbearable pain). Pressure-pain threshold was measured with an algometer in newtons; three measurements 10 seconds apart were averaged. Measures were taken before the first session and immediately after session four.

Between-group findings

At baseline, VAS was 4.91±1.76 (treated, n=9) and 4.89±1.76 (control, n=11); pressure threshold was 40.36±9.94 N and 43.67±10.27 N. Immediately after treatment, VAS was 2.27±1.27 and 4.44±2.13; threshold was 61.2±12.16 N and 45.0±9.17 N. Authors report between-group differences after treatment (Mann–Whitney, p<0.05), without exact p-values or effect estimates. Within-group change was significant for treated participants (Wilcoxon, p<0.05) and nonsignificant for control. Within-group tests do not replace the between-group test.

Harms

No participant reportedly withdrew due to side effects. Structured adverse-event counts or surveillance results are not described; this is not proof of zero harms.

Limitations

Authors note sex imbalance, restricted age distribution, single rather than double blinding (examiner knew group), missing disease-duration data and only immediate post-treatment assessment. The study cannot establish duration or broad generalizability. Table 1 is an image in the raw XML and unavailable for visual inspection; group characteristics were taken from narrative text. Figure image assets were unavailable locally.

Applicability

This study reports short-term changes in two pain-related measures after four sessions. It did not assess long-term persistence, everyday function or comparison with medication or exercise.

Next study

Authors call for larger, more diverse samples, later follow-up and comparison with medication, exercise and other treatments; they also suggest mechanistic studies.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal shock wave therapy in myofascial pain syndrome of upper trapezius.

Ji HM, Kim HJ, Han SJ. · Annals of rehabilitation medicine · 2012

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →